Over the past few years, both the National Institutes of Health and the National Science Foundation have put forth large quantities of funding towards life science research onboard the International Space Station U.S. National Laboratory. Why are these funding agencies investing millions into station research? How does the microgravity environment of the space station contribute towards unlocking concepts that could accelerate drug development and design? What are these implications for the drug development community?
Session ID: 553160